ALK and neuroblastoma: Gain-of-function mutations in the ALK (anaplastic lymphoma kinase) oncogene were identified as the genetic etiology of familial neuroblastoma and as the most common somatic single-nucleotide variants in neuroblastoma, positioning ALK as the most frequently mutated oncogene tractable for targeted therapy in neuroblastoma2–5.